Skip to content
Screener
Neurocrine Biosciences logo

Neurocrine Biosciences

NBIX

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for neurological, psychiatric, endocrine, and immunological disorders.

Market cap
$14.88B-2.9%
Revenue$3.4B+34.4%
Net income$705.5M+103%
Free cash flow$870.4M+64.6%
EPS (diluted)$6.82+102%
Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

July 30, 2026
Revenue$959.0MBeat by $67.8MEPS$1.39Miss by $0.26

Next report

Nov 2, 2026 (Today)
Revenue estimate$1.0B
EPS estimate$1.91

Financials

Q2 2026

Income statement

See full
Revenue$959.0M+39.5%
Gross profit$935.8M+38.4%
Operating income$151.5M+4.1%
Net income$144.4M+34.3%
EPS (diluted)$1.39+31.1%

Balance sheet

See full
Cash & equivalents$332.4M+22.2%
Total debt$461.6M-5.8%
Total equity$3.7B+37.1%
Total assets$5.4B+37.8%

Cash flow

See full
Operating cash flow$136.4M+33.7%
CapEx$7.8M-37.6%
Free cash flow$128.6M+43.7%

Valuation & ratios

Valuation

See full
Market cap$14.88B-2.9%
Enterprise value$15.01B+8.0%
P/E21.1×-11.1×
P/S4.4×-0.7×

Profitability

See full
Gross margin98%-0.5pp
Operating margin23.6%+3.8pp
Net margin20.9%+7.0pp
FCF margin25.8%+4.7pp

Returns & leverage

See full
Return on equity22.1%+8.7pp
Debt / equity0.1×-0.1×
Current ratio1.9×-1.3×

Segments

By segment

See full
Reportable Segment$959.0M+39.5%

By product

See full
Collaboration revenues$4.7M-14.5%

Competitors

By market cap

Bristol-Myers Squibb logo
Bristol-Myers Squibb$125.49B+35.1%
Neurocrine Biosciences logo
Neurocrine Biosciences$14.9B+8.1%
Acadia Pharmaceuticals logo
Acadia Pharmaceuticals$3.6B-6.8%
Solid Biosciences Inc. logo
Solid Biosciences Inc.$685.2M+65.7%
Ovid Therapeutics logo
Ovid Therapeutics$500.0M+413%
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc.$429.0M-43.6%
SPR
Spruce Biosciences, Inc.$134.6M+123%
Neumora Therapeutics, Inc. logo
Neumora Therapeutics, Inc.$73.0M-84.6%

By revenue growth

Neurocrine Biosciences logo
Neurocrine Biosciences+34.4%
Acadia Pharmaceuticals logo
Acadia Pharmaceuticals+11.8%
Bristol-Myers Squibb logo
Bristol-Myers Squibb+4.2%

By net margin

Acadia Pharmaceuticals logo
Acadia Pharmaceuticals33.42%+11.6pp
Neurocrine Biosciences logo
Neurocrine Biosciences20.91%+7.0pp
Bristol-Myers Squibb logo
Bristol-Myers Squibb18.47%+6.0pp
Solid Biosciences Inc. logo
Solid Biosciences Inc.-1,062.28%—

Profile

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for neurological, psychiatric, endocrine, and immunological disorders. The company's value proposition is centered on addressing significant unmet medical needs through a portfolio of approved treatments and a diversified pipeline of small molecules and biologics. Its primary revenue driver is a leading treatment for tardive dyskinesia and Huntington's disease chorea.

Competitive position

A leading neuroscience company with the first FDA-approved treatment for tardive dyskinesia and a dominant position in the VMAT2 inhibitor market.

GeographiesUnited States, Japan, Asia
Customer segmentsPatients, Healthcare Providers, Specialty Pharmacies
Business modelResearch and Development, Direct-to-market pharmaceutical sales, Licensing and Royalties
SuppliersThird-party contract manufacturers (CMOs), Active pharmaceutical ingredient (API) suppliers, Third-party logistics providers
CustomersSpecialty pharmacies, Pharmaceutical wholesalers, Hospitals and long-term care facilities, Endocrinology and neurology clinics
CountryUnited States of America
Listed1996
Employees1.4K
CEOKyle W. Gano
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Websiteneurocrine.com
FilingsSEC EDGAR

FAQ

What is Neurocrine Biosciences's market cap?
Neurocrine Biosciences (NBIX) has a market capitalization of $14.9B and trades on NASDAQ.
What is Neurocrine Biosciences's revenue and profitability?
Neurocrine Biosciences generated $3.4B in trailing twelve-month revenue with net income of $705.5M, representing a net margin of 20.9%. Gross margin stands at 98.0%, with free cash flow of $870.4M. The latest reported period is Q2 2026.
Who are Neurocrine Biosciences's competitors?
Neurocrine Biosciences's key competitors include Acadia Pharmaceuticals Inc., Bristol-Myers Squibb, Neumora Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Neurocrine Biosciences partner with?
Neurocrine Biosciences's notable partners include AbbVie Inc., Takeda Pharmaceutical Company Limited, Nxera Pharma UK Limited, and others.
Where is Neurocrine Biosciences headquartered?
Neurocrine Biosciences is headquartered in United States of America and employs approximately 1,448 people. It has been publicly traded since 1996.